Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 15

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 15
---
 and an M.D. from Vanderbilt University, and completed internal medicine training at Johns Hopkins Hospital and subspecialty training in pulmonary and critical care medicine at the University of California, San Francisco. We believe Dr. Flemings’s extensive background in the healthcare industry and experience working closely with biopharmaceutical companies provides him with the appropriate set of skills to serve as a member of our board of directors. Peter A. Thompson, M.D.has served as a member of our board of directors since February 2022. Dr. Thompson is a member at OrbiMed Advisors LLC, an investment firm, where he has served in various roles of increasing responsibility since 2010, including as Partner from 2013 to 2021. Dr. Thompson currently serves on the boards of directors of ARS Pharmaceuticals Inc. (formerly Silverback Therapeutics, Inc.) (NASDAQ: SPRY), since April 2016, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), since November 2014, and Edgewise Therapeutics, Inc. (NASDAQ: EWTX), since May 2017, as well as several private companies. Previously, Dr. Thompson served on the boards of directors of Alpine Immune Sciences, Inc. (NASDAQ: ALPN), Decibel Therapeutics, Inc. (NASDAQ: DBTX), Janux Therapeutics, Inc. (NASDAQ: JANX), PMV Pharmaceuticals, Inc. (NASDAQ: PMVP), Prevail Therapeutics Inc. (NASDAQ: PRVL) and Synthorx, Inc., until its acquisition by Sanofi. Dr. Thompson previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation and Becton, Dickinson and Company. Dr. Thompson is also an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School. We believe Dr. Thompson’s management and venture capital experience in the biopharmaceutical industry provides him with the appropriate set of skills to serve as a member of our board of directors. Joanne Louise Viney, Ph.D.has served as a member of our board of directors since January 2025. Dr. Viney is a co-founderand has served as the chief executive officer of Seismic Therapeutic, Inc. (“Seismic”) since October 2021. Prior to that, Dr. Viney co-foundedand served as the chief scientific officer